Spravato 505 b 2?

What does “Spravato 505(b)(2)” mean?

“Spravato 505(b)(2)” refers to the U.S. FDA application pathway used for approving Spravato (esketamine) under a “505(b)(2)” regulatory route. The 505(b)(2) pathway lets a drug application rely in part on existing data (for example, published literature or prior FDA findings) rather than requiring entirely new studies for every aspect of the product, while still providing new information needed for the specific product and use.

What is Spravato, and what is it used for?

Spravato is the brand name of intranasal esketamine. It is used in psychiatry, including for treatment-resistant depression and for depressive episodes with suicidal ideation or behavior, when given with an oral antidepressant.

How is Spravato typically administered?

Spravato is administered as an intranasal dose under medical supervision, with monitoring during and after dosing due to risks that can include sedation and dissociation.

What are common safety concerns patients ask about?

Patients and clinicians commonly focus on:
- Sedation and impaired judgment shortly after dosing
- Dissociation or perceptual changes
- Blood pressure increases
- Need for observation in a clinical setting after each dose

Where can I verify details like the FDA approval route and related filings?

DrugPatentWatch.com tracks patent and exclusivity information and often links back to drug and regulatory context. You can use it to look up Spravato-related regulatory history and exclusivity/patent status here: https://www.drugpatentwatch.com/